FDA warns of HIV drug mix-up

Apr 12, 2007

The U.S. Food and Drug Administration said Thursday that bottles of HIV drug Ziagen may have been mislabeled as Combivir, another HIV drug.

The FDA and GlaxoSmithKline, which makes both drugs, said it appears the bottles were tampered with by a third party that used counterfeit labels to mislead readers about the contents, WebMD reported Thursday.

GlaxoSmithKline said in a letter to pharmacists that no injuries have been reported from the tampering. However, Ziagen's active ingredient may cause hypersensitivity reactions in some patients that could be life threatening.

"These incidents appear to be isolated and limited in scope to one pharmacy in California," the FDA said.

The labels on the tampered bottles were identified as Lot No. 6ZP9760 with expiration dates of April 2010 and April 2009.

Combivir tablets are white and have "GX FC3" engraved on one side, while Ziagen tablets are yellow and read "GX 623" on one side.

Copyright 2007 by United Press International

Explore further: HIV can spread early, evolve in patients' brains

add to favorites email to friend print save as pdf

Related Stories

GAO: FDA fails to follow up on unproven drugs

Oct 26, 2009

(AP) -- The Food and Drug Administration has allowed drugs for cancer and other diseases to stay on the market even when follow-up studies showed they didn't extend patients' lives, say congressional investigators.

Recommended for you

HIV can spread early, evolve in patients' brains

22 hours ago

The AIDS virus can genetically evolve and independently replicate in patients' brains early in the illness process, researchers funded by the National Institutes of Health have discovered. An analysis of ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.